Pharmacological Targets in Metabolic Diseases
Challenges and Opportunities
- 1st Edition - September 26, 2025
- Latest edition
- Editor: Marcos Roberto de Oliveira
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 7 3 7 0 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 7 3 7 1 - 1
Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic develo… Read more
Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic developments. Covering both signaling pathways and specific proteins, the book presents ways to modulate the molecular and cellular alterations observed in metabolic diseases and disorders through the application of new or classical drugs. The comprehensive coverage starts by providing an overview of metabolic diseases and disorders, biological alterations, and pharmacological targets. This section covers targets at both molecular, and subcellular and cellular levels. The next section in the book is focused on pharmaceutical targeting of organs, including a dedicated chapter to the gut-brain axis. Next comes a thorough review of the current advances in metabolic syndrome research. Section VI is focused on inborn errors of metabolism and is followed by a section devoted to natural molecules and their pharmacological potential to treat these conditions. The Editor introduces next a whole section dedicated to the role of the microbiota in metabolic diseases therapeutics. The following sections cover the impact of aging, nanotechnology, the environment, and finally diagnostic techniques in metabolic diseases and disorders. Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities meet the needs of pharmacology researchers looking for a comprehensive and authoritative source of information on possible therapeutic targets to treat these conditions. Research physicians, nutritionists, pharmacists, and biologists can benefit from the detailed information provided at the different levels of targets identified to treat metabolic diseases and conditions.
- Covers the most prevalent metabolic diseases and disorders such as metabolic syndrome, diabetes mellitus (types I and II) and dyslipidemia, among others
- Includes chapters on the microbiome and environmental pollution as they relate to metabolic diseases and conditions
- Discusses cellular structures like the endoplasmic reticulum and mitochondria as pharmacological targets
Academic and corporate researchers in Pharmacy, Pharmacology, Biology, and Nutrition.
Part I: Subsection: Overview of metabolic diseases and disorders, biological alterations, and pharmacological targets
Section I: Molecular level
1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview
2. Pharmaceutical aspects of conventional and recent developments for the treatment of metabolic diseases and disorders
3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity
4. Targeting reactive carbonyls in metabolic disorders
Section II: Subcellular and cellular levels
5. Targeting autophagy in metabolic diseases
6. Endoplasmic reticulum as a pharmacological target in metabolic diseases
7. Pharmacologically targeting caveolae in metabolic diseases
Part II: Subsection: Organs as pharmacological targets in metabolic diseases and disorders
8. The gut-brain axis as a pharmacological target for depressive disorder and Alzheimer’s disease in diabetes {i|mellitus}
9. Cardiomyopathy in metabolic diseases: pharmacological strategies
10. Diabetic kidney disease: treatment and challenges
11. Unraveling the Enigma of Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Therapeutic Horizons
12. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Part III: Subsection: Obesity
13. Pharmacological targets in obesity
14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseases
Part IV: Subsection: Metabolic syndrome
15. Metabolic syndrome: pharmacological strategies and challenges
16. Pharmacological targets in metabolic syndrome-related dyslipidemia
17. Plant molecules and metabolic syndrome: therapeutic opportunities
Part V: Subsection: Natural molecules and metabolic diseases and disorders
18. Polyphenols and obesity: molecular targets and therapeutic potential
19. Plant Molecules: Prevention and Management of Diabetes Mellitus
20. Molecular targets in dyslipidemia: therapeutic potential of plant molecules
21. Polyphenols and the control of immunometabolism as a pharmacological target
Part VI: Subsection: Microbiota and metabolic diseases and disorders
22. Microbiota, metabolic disorders and pharmacological opportunities
23. Gut microbiota as a pharmacological target in cardiovascular diseases
24. Plant molecules in obesity and the gut microbiota
25. Microbiota and fatty liver disease: potential candidate for therapeutic intervention
Part VII: Subsection: Nutrition and food interactions
26. Nutrition and Drug Interactions in Metabolic Diseases
Section I: Molecular level
1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview
2. Pharmaceutical aspects of conventional and recent developments for the treatment of metabolic diseases and disorders
3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity
4. Targeting reactive carbonyls in metabolic disorders
Section II: Subcellular and cellular levels
5. Targeting autophagy in metabolic diseases
6. Endoplasmic reticulum as a pharmacological target in metabolic diseases
7. Pharmacologically targeting caveolae in metabolic diseases
Part II: Subsection: Organs as pharmacological targets in metabolic diseases and disorders
8. The gut-brain axis as a pharmacological target for depressive disorder and Alzheimer’s disease in diabetes {i|mellitus}
9. Cardiomyopathy in metabolic diseases: pharmacological strategies
10. Diabetic kidney disease: treatment and challenges
11. Unraveling the Enigma of Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Therapeutic Horizons
12. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Part III: Subsection: Obesity
13. Pharmacological targets in obesity
14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseases
Part IV: Subsection: Metabolic syndrome
15. Metabolic syndrome: pharmacological strategies and challenges
16. Pharmacological targets in metabolic syndrome-related dyslipidemia
17. Plant molecules and metabolic syndrome: therapeutic opportunities
Part V: Subsection: Natural molecules and metabolic diseases and disorders
18. Polyphenols and obesity: molecular targets and therapeutic potential
19. Plant Molecules: Prevention and Management of Diabetes Mellitus
20. Molecular targets in dyslipidemia: therapeutic potential of plant molecules
21. Polyphenols and the control of immunometabolism as a pharmacological target
Part VI: Subsection: Microbiota and metabolic diseases and disorders
22. Microbiota, metabolic disorders and pharmacological opportunities
23. Gut microbiota as a pharmacological target in cardiovascular diseases
24. Plant molecules in obesity and the gut microbiota
25. Microbiota and fatty liver disease: potential candidate for therapeutic intervention
Part VII: Subsection: Nutrition and food interactions
26. Nutrition and Drug Interactions in Metabolic Diseases
- Edition: 1
- Latest edition
- Published: September 26, 2025
- Language: English
MO
Marcos Roberto de Oliveira
Marcos Roberto de Oliveira, PhD earned his bachelor’s degree in Biological Sciences at Federal University of Rio Grande do Sul (UFRGS) in 2005, followed by a master’s and a Ph.D. in Biochemistry from the same institution. He is currently a professor and coordinates research at UFRGS. His research focuses on the neuroprotection mediated by natural molecules and involves studies on mitochondrial physiology, redox biology, bioenergetics, and inflammation in both in vitro and in vivo experimental models.
Affiliations and expertise
Professor, Department of Biochemistry, Federal University of Rio Grande do Sul, Universidade Federal do Rio Grande do Sul (UFRGS), Instituto de Ciências Básicas da Saude (ICBS), Departamento de Bioquímica, Rua Ramiro Barcelos, BrazilRead Pharmacological Targets in Metabolic Diseases on ScienceDirect